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Rapid testing of appropriate specimens from patients suspected for a disease during an
epidemic, such as the current Coronavirus outbreak, is of a great importance for the
disease management and control. We propose a method to enhance processing large
amounts of collected samples. The method is based on mixing samples in testing tubes
in a specific configuration, as opposed to testing single samples in each tube, and ac-
counting for natural virus amounts in infected patients from variation of positiveness in
test tubes. To illustrate the efficiency of the suggested method we carry out numerical
tests for actual scenarios under various tests. Applying the proposed method enhances
the number of tests by order of magnitudes, where all positives are identified with no
false negatives, and the effective testing time can be reduced drastically even when the
uncertainty in the test is relatively high.
The World Health Organization has declared the growing epidemic of novel coronavirus
infectious disease (COVID-19) a global pandemic. The virus emerged in Wuhan, China, at
the end of 2019, and as of April 22, 2020 over two and a half million cases were identified
in 210 countries and territories, with nearly 180,000 deaths being reported1. In most coun-
tries around the world the number of cases is believed to be much larger than reported. The
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relatively low reported number is attributed to a number of factors, including but not limited
to mismanagement of the epidemic at the political level, high ER visit costs, and a lack of re-
sources that limit the number of tests drastically. For example in the UK 25,000 tests were
carried out in the period since January 2020 and up until March 11, 2020, which is equivalent
to the number of tests carried out in South Korea in two and half days according to the World
Health Organization. Thus, while in some countries there is a (front-end) problem of sample
collection, in other countries the main concern is in processing the collected samples (back-
end problem). Here we are concerned with the back-end problem, namely processing a large
amounts of collected samples.
Specimens can be collected from the upper respiratory tract as nasopharyngeal (through
the nose) and oropharyngeal (through the mouth) swab or wash in an ambulatory regime2.
The laboratory confirmation of the COVID-19 is based on the Nucleic Acid Amplification Tests
(NAAT); the assay detects the genomic sequences of virus RNA by real-time reverse transcrip-
tion polymerase chain reaction rRT-PCR.
The current outbreak has evoked researchers and experts from various fields to reevaluate
the feasibility of multi-sample pools3,4, where samples from a number of patients are mixed
together, as opposed to testing individual samples. In this work, we propose an advanced
testing method where samples from each patient are mixed in multiple tubes in a unique con-
figuration, then variation of test “positiveness” of each tube are employed in order to calculate
all possible positives. The first part of the method is by itself powerful when the percentage
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of infected patients is extremely low, as long as proper mixing is done – keeping in mind the
dilution threshold (due to mixing) required for identifying the disease. However, as the per-
centage of the infected increases it becomes much more challenging to determine positives
without performing new tests. To this end, an accurate quantitative approach (the second part
of the proposed method) can be employed to determine all positives without risking having
false negatives. For this part to be effective, an accurate method for quantification of PCR is
required5. The proposed method takes into account the uncertainty (error) in the test. Even
when the uncertainty increases (i.e. for less accurate tests), all positives are still obtained with
no false negatives, though false positives start to arise as well. The mathematical model of the
proposed method is presented in the following section.
1 Variation of positiveness: Mathematical model
Let n be the number of patients (sample size), m the size of the test tube set, and l the size of
a subset of the tube test set. Each patient sample is distributed to a different configuration of
l tubes. Thus, the maximum number of patients is given by
n=
m!
l! (m− l)! (1)
The test results in each tube j = 1..l can be described by
R j =
n∑
i=1
ri jδi, ( j = 1..l), (2)
where ri j is the contribution of the i-th patient to the ‘positiveness’ of the j-th tube, and δi j is
the delta function, being zero or unity for negatively or positively tested patients, respectively.
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Thus, we can now construct a set of n algebraic equations
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...
. . . . . . . . . . . . . . .
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0 . . . . . . . . . rn rn rn
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T 
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=
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
(3)
or for simplicity we write rTδ = R, where subscript T is the transpose operator. The solution
vector R represents the test results, and thus known with some degree of test uncertainty, ∆R,
which we shall account for. On the other hand, while the matrix r is unknown, the distributions
of the samples in the tubes is our choice, and that is simply the matrix r with nonzero elements
replaced by ones,
Ii, j =

1 1 1 . . . . . . 0 0
1 1 0 1 . . . 0 0
...
. . . . . . . . . . . . . . .
...
0 . . . . . . . . . 1 1 1

(4)
which is the distribution matrix (n × l) that shows how samples from each patient (rows)
are added to the tubes (columns). Finally, the vector δ contains the information we seek, on
positive and negative patients. Thus, our objective is find δ.
Phase 1: Identifying immediate negatives. The test results vector R may contain zero el-
ements (i.e. tests that return negative). For each test tube j that returns zero, i.e. R j = 0,
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all patients i that have Ii, j = 1 should test negative, otherwise the test tube would not have
returned zero (R j 6= 0). Thus, at this phase we are able to identify q patients that are negatives,
with 0≤ q ≤ n.
Phase 2: Identifying all positives. We rewire equation (3), excluding the negatives identified
in the previous phase as r˜T δ˜ = R˜. Thus, all elements of R˜ are now non zero. In order to
identify all positives we seek all possible solutions for δ˜, using (n − q) algebraic equations,
for each possible solution δ˜. Now we carry out the following programme: (i) Consider all
combinations that have a single positive, i.e. exactly (n− q) combinations. Note that this can
be the case only when elements in R˜ are identical, within the test uncertainty∆R. (ii) Consider
all combinations with two positives, which is also easy to identify/exclude as it requires R˜ to
have either two or three different elements; two numbers that each corresponds to one of the
positive patients, and possibly a third in case they are combined in a third tube. (iii) In general,
we keep add an additional possible positive (i.e. increase the number of 1’s in R˜ ), and seek
for a solution.
Phase 3: Identifying more negatives. All patients that were not identified positive in phase
2, nor negative in phase 1, have to be negative, as all positives have been identified. Thus all
patients with i(δ˜k = 0) are identified as negative.
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2 Results & discussion
To gain more quantitative understanding of the proposed method, we performed numerical
tests with actual scenarios under various conditions. We considered group sizes of 28, 56, and
70 patients that were tested using 8 tubes only (figure 1), and group sizes of 120, 210 and
252 patients using 10 tubes - see figure 2. Infected patients were selected randomly, with a
percentage that ranged from 0.8 to 21.43. Each result point is an average of a hundred test
repetitions, which is important when discussing uncertainties in the tests that were allowed to
be between ∆R = 0.05%...30%. Without loss of generality, each of the positively tested pa-
tients were allocated a random number between 0-220 nano grams (ng), that mimics possible
reading, e.g. using a PCR technique, though any other range could be equally implemented.
Uncertainty in the test results, ∆R, depends on a number of factors among which are the
accuracy and precision of the test method. The less sensitive the test is the larger∆R becomes,
e.g. an uncertainty of 10% is equivalent to 20 ng so that we are unable to distinguish between
two readings with difference that is less than 20 ng. Therefore, as ∆R increases false solutions
may appear, and thus false positive results are expected. However, since the actual solution lies
within any given uncertainty, we never obtain false negatives, which is extremely important
for disease management and control. If the uncertainty is very small, we are always able
to obtain a single solution δ that determines accurately all positively and negatively tested
patients. Unfortunately, current technology is associated with a degree of uncertainty that
requires optimising the solution using other factors such as tube set size m, and subset l. The
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smaller the percentage of infected patients, the higher the percentage of negatives identified
(figure 1). As the uncertainty increases, the size of subset l becomes important. Having a
smaller l size results in a higher percentage of negatives, though the size of the group n becomes
smaller (figure 2 and eq.(1)). When m and l increase the length of δ˜ becomes larger, which
requires solving for a greater combination of possible solutions. If the uncertainty in the tests
is large, finding a solution and determining the positives is not always possible, though if
solutions are found we always determine all positives, even if there are false positives. For
example, for 252,000 patients, we performed 100 independent tests with 10 tubes each, and
allowed each patient samples to be distributed to 5 tubes (see right subplot of figure 2, blue-
cross curve), even at high uncertainty of 32.77 ng (14.9% error), we were able to determine
all positives in 90 tests out of 100 tests that were carried out. Thus, all positives from 226,800
patients were determined. In the remaining 8 tests, no solution was found and thus there is no
risk for false negatives, in any of the tests. However, in this case we are only able to determine,
on average 67.67% of all negatives in all 100 tests (see left subplot of figure 2, blue-cross
curve). If a more accurate test is applicable, say with an uncertainty of 2.048 ng (' 1% error),
%99.6 of all negatives are identified in all 100 tests. Note that in figure 2 the percentage of
positives is variable and selected randomly to mimic an actual scenario were we don’t know
the percentage of infected patients a priori.
Although attention was focused here on enhancing lab tests for COVID-19, in particular,
and epidemics in general, we believe that the proposed method can be equally implemented in
a variety of lab tests. In fact, once the solutions vector δ is obtained one could structure back
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quantities in each of the infected samples, i.e. r = RTδ. Such a quantitative method could
be complementary to a wide range of environmental, healthcare and safety, and engineering
applications, e.g. for testing contaminated water or food, spread of diseases in population and
sewage, and proper concentration of substances in chemical products.
Methods
Numerical analysis For the numerical calculations, we used a MacBook Pro, 2.8 Ghz Quad-
Core Intel Core i7 processor, 16GB 1600 Mhz DDR3 memory. A code has been developed in
Matlab R18a. An example of the output for a single test can be found in the supplementary
information.
Calculation algorithm
• Each patient is allocated a binary number with l one’s and (m− l) zero’s, e.g. (0 0 1 0 1
1 0 . . . ). The location of each digit of the binary number corresponds to a single tube (m
tubes in total), e.g. the first digit from left (0) corresponds to the first tube, the second
digit (0) corresponds to the second tube, the third digit (1) corresponds to the third tube,
etc.
• Samples from each patient are added to all tubes that correspond to digits with number
‘1’. For example, samples from patient (0 0 0 1 1 1) are added to tubes number 4, 5, and
8
6 (from left).
• All m tubes are sent for testing. It is important that testing is obtained at a cycle where
no saturation has been reached, so that the value of each positive test represents a sum-
mation of unique values for each positive sample in that tube. A quantitative result (RT)
is obtained in the following form:
0 34.0972 159.3790 125.2818 159.3790 0 0 159.3790 . . .
• All tubes that return negative indicate that all patients that have samples in that tubes
are not infected (negatives).
• Given the test results and uncertainty within, we then calculate all possible combina-
tions of solutions δ˜ that return R˜, which when found, return all positives, and possibly
additional negatives.
• In the unlikely scenario of no solution, a repeated test for all unidentified samples is
required. This can be done by reshuffling samples, or splitting them between other test
groups.
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Figure 1 Fixed number of positives. Uncertainty analysis in tests using 8 tubes (m = 8),
for fixed number of randomly selected positives, ranging from 2.86% to 21.43% of total patients.
Each calculation point is an average of 100 repetitions. Left column: percentage of negative patients
successfully identified. Right column: solutions found for positive patients (note that once a solution
is found 100% of positives are identified). Rows top to bottom: l = 3, 4, and 5, with n= 28, 56, and
70, respectively.
Figure 2 Random number of positives. Uncertainty analysis in tests for random number of
positives (randomly selected), ranging from 0.8% to 5% of total patients. Using 10 tubes (m = 10),
and l = 3, 4, and 5, corresponding to a total number of patients n= 120, 210, and 252, respectively.
Left plot: percentage of negative patients successfully identified. Right column: solutions found for
positive patients (note that once a solution is found 100% of positives are identified).
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